



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

JAGSONPAL PHARMACEUTICALS LTD. CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION.

1. Corporate Disclosure Policy

- 1.1. The following is the Corporate Disclosure Policy/norm to be followed by Jagsonpal Pharmaceuticals Limited. ("Company") to ensure timely and adequate disclosure of price sensitive information.
- 1.2. For the purpose of this Code Unpublished Price Sensitive Information ("UPSI") shall mean and include such matters as may be specified under the SEBI (Prohibition of Insider Trading) Regulations, 2015 and any amendment thereto from time to time (hereinafter referred to as "Regulations").
- 1.3. This Code shall be applicable and binding on all the persons as defined under the regulations which shall include employees, officers, directors and those persons authorized to speak on behalf of the Company.

2. Prompt disclosure of price sensitive information

- 2.1. Disclosure of UPSI would be done promptly when credible and concrete information is available for making the same generally available;
- 2.2. the company will endeavour to make uniform and universal dissemination of UPSI and will avoid making selective disclosure once the information is ready to be made generally available. Material events will be disseminated as mandated by the stock exchanges in Clause 36 of the Listing Agreement as amended from time to time.
- 2.3. In case the Company is required to make selective disclosure of UPSI, then the information will be promptly disseminated either in the form of notification to stock exchanges, press releases or upload of information on the website of the Company.
- 2.4. UPSI handling will be on a selective need to know basis for legitimate purposes only.
- 2.5. The information released to stock exchanges will also be placed on the website of the Company for improving investor access to such public announcements.

3. Overseeing and co-ordinating disclosure

- 3.1. The Chairman & Managing Director (CMD), or the Company Secretary, being the person who is designated as the Compliance Officer to oversee corporate disclosure will be the Compliance Officer (CO) to deal with dissemination of information and disclosure of UPSI.
- 3.2. The CMD or CO shall be responsible for ensuring that the Company complies with continuous disclosure requirements, overseeing and co-ordinating disclosure of price sensitive information to stock exchanges, analysts, shareholders and media, and educating staff on disclosure policies and procedure.
- 3.3. Information disclosure/dissemination may normally be approved in advance by the CMD or CO.



Contd...2



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 264947082 Phone : 0091-11-26494519-24

3.4. If information is accidentally disclosed without prior approval, the person responsible may inform the CMD or CO immediately, even if the information is not considered price sensitive.

4. Responding to market rumours

- 4.1. Any queries or requests for verification of market rumours by exchanges should be forwarded immediately to the CMD or CO who shall decide on the response/clarification.
- 4.2. The CMD or CO shall decide whether a public announcement is necessary for verifying orderying rumours. The required disclosure shall be made accordingly.
- 4.3. The Company will, subject to non-disclosure obligations, aim to provide appropriate and fair response to the queries on news reports and requests for verification of market rumours by regulatory authorities.
- 4.4. As a general practice, if the rumour appears in a responsible media channel which has reasonably wide audience and rumour can have material impact on pricing of securities, then the Company would immediately make a proper announcement to present the correct position.

5. Timely Reporting of shareholdings/ownership and changes in ownership:

- 5.1. Disclosure of shareholdings/ownership by major shareholders and disclosure of changes in ownership as provided under any Regulations made under the Act and the listing agreement shall be made in a timely and adequate manner.

6. Disclosure/ dissemination of Price Sensitive Information with special reference to Analysts, Institutional Investors

6.1. The guidelines given here under shall be followed while dealing with analysts and institutional investors:-

- i. Only Public information to be provided
Only public information and Non Price Sensitive Information should be provided to the analyst/research persons. Alternatively, the information given to the such persons should be made generally available at the earliest.
- ii. Handling of unanticipated questions
Sufficient care should be exercised while dealing with analysts' questions that raise issues outside the intended scope of discussion. Unanticipated questions may be taken on notice and suitable response given later. If the answer includes price sensitive information, the same should be promptly made generally available.
- iii. Prompt release of Information
The Company may also consider transcripts or records of the proceedings of the meetings with Analysts, Investor Relation meetings available on the website of the Company promptly.



Contd...3



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

-3-

7. Medium of disclosure/dissemination

7.1 The manner of disclosure/ dissemination of UPSI is given below:-

- i. Disclosure/ dissemination of information may be done through newspapers and company's website as to achieve maximum reach and quick dissemination.
- ii. CMD or CO shall ensure that disclosure to stock exchanges is made promptly.
- iii. Company may also facilitate disclosure through the use of their dedicated Internet website.
- iv. Company websites may provide a means of giving investors a direct access to analyst Briefing material, significant back ground information and question and answers.
- v. The information filed by the Company with exchanges under continuous disclosure requirements may be made available on the Company's website.

8. Amendments and Modifications

8.1. This code shall be reviewed from time to time and any amendments or modifications thereto shall be subject to the review and approval of Board of Directors of the Company.

9. Effective Date

9.1. This Code is effective from May 15, 2015.

Jagsonpal Pharmaceuticals Limited

T-210 J, Shahpur
New Delhi - 110 049
Tel: +91 11 46181100
Fax: +91 11 2649 341

Website : jagsonpal.com

Email : cs@jagsonpal.com

Company's CIN : L74899DL1978PLC009181

